Table 4.
Relationship between length of non-steroideal anti-inflammatory drug consumption and breast cancer, according to women’s characteristics
| Population | NSAID | No consumption | Consumption ≤5y | Consumption >5y | ||
|---|---|---|---|---|---|---|
| Controls/cases (n) | Controls/cases (n) | OR (95 % CI) | Controls/cases (n) | OR (95 % CI) | ||
| All women | NSAID (all) | 1171/1111 | 484/445 | 0.81 (0.67–0.98) | 255/180 | 0.64 (0.50–0.83) |
| Aspirin | 1808/1653 | 79/70 | 0.99 (0.67–1.46) | 23/13 | 0.65 (0.31–1.38) | |
| Acetic acid derivatives | 1754/1620 | 113/86 | 0.75 (0.53–1.06) | 43/30 | 0.75 (0.42–1.32) | |
| Propionic acid derivatives | 1351/1232 | 380/364 | 0.86 (0.71–1.06) | 179/140 | 0.73 (0.55–0.97) | |
| NSAID others | 1862/1697 | 33/35 | 1.47 (0.83–2.60) | 15/4 | - | |
| Premenopausal | NSAID (all) | 361/415 | 162/187 | 0.82 (0.59–1.13) | 105/100 | 0.78 (0.52–1.17) |
| Aspirin | 613/689 | 12/12 | 0.72 (0.27–1.95) | 3/1 | - | |
| Acetic acid derivatives | 600/664 | 21/27 | 0.68 (0.35–1.34) | 7/11 | 1.02 (0.31–3.32) | |
| Propionic acid derivatives | 392/461 | 146/167 | 0.85 (0.61–1.19) | 90/84 | 0.81 (0.52–1.25) | |
| NSAID others | 618/693 | 6/8 | 2.38 (0.63–9.00) | 4/1 | - | |
| Postmenopausal | NSAID (all) | 805/696 | 312/258 | 0.77 (0.61–0.98) | 150/80 | 0.53 (0.38–0.75) |
| Aspirin | 1181/964 | 66/58 | 1.08 (0.70–1.66) | 20/12 | 0.74 (0.33–1.65) | |
| Acetic acid derivatives | 1143/956 | 88/59 | 0.76 (0.50–1.15) | 36/19 | 0.61 (0.31–1.20) | |
| Propionic acid derivatives | 954/781 | 224/197 | 0.84 (0.64–1.09) | 89/56 | 0.64 (0.43–0.95) | |
| NSAID others | 1229/1004 | 27/27 | 1.27 (0.66–2.42) | 11/3 | - | |
| BMI <25 | NSAID (all) | 578/537 | 233/183 | 0.78 (0.58–1.04) | 131/99 | 0.65 (0.45–0.94) |
| Aspirin | 901/794 | 32/22 | 0.84 (0.43–1.63) | 9/3 | - | |
| Acetic acid derivatives | 883/783 | 44/22 | 0.40 (0.20–0.77) | 15/14 | 1.16 (0.42–3.15) | |
| Propionic acid derivatives | 656/575 | 191/163 | 0.89 (0.66–1.21) | 95/81 | 0.80 (0.52–1.22) | |
| NSAID others | 919/806 | 14/11 | 1.51 (0.56–4.06) | 9/2 | - | |
| BMI >25 | NSAID (all) | 593/574 | 251/262 | 0.84 (0.65–1.08) | 124/81 | 0.61 (0.43–0.86) |
| Aspirin | 907/859 | 47/48 | 1.10 (0.68–1.80) | 14/10 | 0.74 (0.30–1.82) | |
| Acetic acid derivatives | 871/837 | 69/64 | 0.94 (0.61–1.44) | 28/16 | 0.54 (0.27–1.10) | |
| Propionic acid derivatives | 695/657 | 189/201 | 0.85 (0.64–1.12) | 84/59 | 0.64 (0.43–0.95) | |
| NSAID others | 943/891 | 19/24 | 1.44 (0.71–2.95) | 6/2 | - | |
OR Odds ratio adjusted for age, recruitment area, education level, tobacco smoking history, BMI family history of breast cancer, number of deliveries, age at first delivery, menarche age, and menopausal status. CI confidence interval